Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Neuronetics (Malvern, PA) a commercial-stage medical device company focused on pulsed magnetic field stimulation for non-invasive, non-systemic treatment of depression, closed a $30M Series E financing. Participants include Polaris Venture Partners, Pfizer Venture Investments, Investor Growth Capital, New Leaf Venture Partners, Interwest Partners, Three Arch Partners, Quaker BioVentures and Onset Ventures.

Cameron Health (San Clemente, CA) a commercial-stage medical device company focused on a subcutaneous implantable defibrillator platform, closed a $107M Series E financing. Participants include Alloy Ventures and Delphi Ventures.

Intrexon (Blacksburg, VA) a commercial-stage synthetic biology company focused on modular DNA control systems to enhance capabilities, improve safety and lower cost in human therapeutics, protein production, industrial products, agricultural biotechnology and animal science next generation synthetic biology company, closed a $100M Series E financing. Participants have included Third Security, New River Management, NewVa Capital […]

CardioDx (Palo Alto, CA) a commercial-stage cardiovascular molecular diagnostics company focused on coronary artery disease, cardiac arrhythmia and heart failure, closed a $60M Series E financing. Participants include Longitude Capital, J.P. Morgan, Acadia Woods Partners, Artian Ventures and Briht Capital.

Rib-X Pharmaceuticals (New Haven, CT) a clinical-stage small molecule drug discovery company developing antiinfectives against community acquired pneumonia, chronic bronchitis and complicated skin infections, closed a $20M Series E financing. Participants have included Warburg Pincus, ABS Ventures, Axiom Ventures, EuclidSR Partners, MedImmune Ventures, Oxford Bioscience Partners, SR One and Vox Equity Partners.

SymBio Pharmaceuticals (Japan) a commercial-stage pharmaceutical company focused on non-Hodgkin’s lymphoma, multiple myeloma and other hematological indications, closed a $24M Series E financing. Participants include Cephalon, Nippon Venture Capital, SMBC Venture Capital, MBL Venture Capital and JAFCO.

VertiFlex (San Clamente, CA) a clinical-stage medical device company focused on percutaneous and motion preserving spinal surgery technologies, closed a $14M Series E financing. Participants include New Enterprise Associates, Aberdare Ventures, Alta Partners and Thomas, McNerney & Partners.

Glaukos (Laguna Hills, CA) a clinical-stage ophthalmology medical device company focused on the management of open-angle glaucoma, closed a $29.5M Series E. Participants include OrbiMed, Frazier Healthcare Ventures, InterWest Partners, Domain Associates and Versant Ventures.

VisionCare Ophthalmic Technologies (Saratoga, CA) a commercial-stage medical device company focused on advanced age-related macular degeneration, closed a $31M Series E financing. Participants include Saints Venture Capital, Giza Ventures, Generali Financial Holdings, BSI, Pitango Venture Capital, Three Arch Partners, Onset Ventures and Infinity CSVC Management.

NanoInk (Skokie, IL) a commercial-stage a protein analysis, biomaterial manufacturing and biodiscovery assay kit developer, closed a$65M Series E financing. Participants include Lurie Investment Fund.

Accuri Cytometers (Ann Arbor, MI) a commercial-stage device company focused on flow cytometery solutions for the R&D market, closed a $6M Series E financing. Participants include Arboretum Ventures, Baird Venture Partners, Fidelity Biosciences, Flagship Ventures and InvestMichigan.

Complete Genomics (Mountain View, CA) a commercial-stage sequencing company building a human genome sequencing center to enable academic and biopharma researchers to conduct large-scale human genome studies, closed a $39M Series E financing. Participants include Sands Capital Management, Essex Woodlands, OVP Venture Partners, Prospect Venture Partners, OrbiMed Advisors, Highland Capital Management and Enterprise Partners.

Gemin X Pharmaceuticals (Malvern, PA) a clinical-stage biopharmaceutical company focused on chronic lymphocytic leukemia, melanoma, small cell lung cancer, lymphoma, myeloma and glioblastoma multiforme, closed a $8M Series E financing. Participants include Caxton Advantage Life Sciences Fund and Sanderling Ventures.

« Previous Page« Previous Entries  Next Entries »Next Page »

to top of page...